Compare Novo Nordisk A/S (NVO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Royal Caribbean Cruises Ltd — how do they compare? Novo Nordisk A/S trades at $45.17 (market cap $200.69B), while Royal Caribbean Cruises Ltd trades at $260.9 (market cap $70.74B). The key difference: Novo Nordisk A/S is far larger — about 2.8× Royal Caribbean Cruises Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | RCL | |
|---|---|---|
Market Cap | $200.69B | $70.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $350.23 |
52-Week Low | $35.29 | $246.71 |
Enterprise Value | $215.49B | $93.38B |
Dividend Yield | 3.98% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Royal Caribbean (RCL) trades at $264.5, down 0.26% on the day, with a bearish technical signal from moving averages but bullish oscillators. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $4.21 versus $3.98, and robust profitability margins including a 23.54% net income margin. Recent news highlights dividend declarations and institutional buying interest, though oil price increases pose near-term headwinds for cruise operators.
The outlook remains positive with analyst consensus price target of $367.83 implying significant upside, supported by earnings growth and debt reduction trends. Key risks include fuel cost volatility from rising oil prices and macroeconomic sensitivity, but institutional accumulation and strong cash flows provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
